Department of Psychiatry, University of California San Diego (UCSD) School of Medicine, San Diego, CA 92093;
Department of Neurosciences, UCSD School of Medicine, San Diego, CA 92093.
Proc Natl Acad Sci U S A. 2020 Feb 4;117(5):2656-2662. doi: 10.1073/pnas.1916570117. Epub 2020 Jan 15.
Slow response to the standard treatment for depression increases suffering and risk of suicide. Ketamine, an -methyl-d-aspartate (NMDA) receptor antagonist, can rapidly alleviate depressive symptoms and reduce suicidality, possibly by decreasing hyperactivity in the lateral habenula (LHb) brain nucleus. Here we find that in a rat model of human depression, opioid antagonists abolish the ability of ketamine to reduce the depression-like behavioral and LHb hyperactive cellular phenotypes. However, activation of opiate receptors alone is not sufficient to produce ketamine-like effects, nor does ketamine mimic the hedonic effects of an opiate, indicating that the opioid system does not mediate the actions of ketamine but rather is permissive. Thus, ketamine does not act as an opiate but its effects require both NMDA and opiate receptor signaling, suggesting that interactions between these two neurotransmitter systems are necessary to achieve an antidepressant effect.
对抑郁症的标准治疗反应缓慢会增加痛苦和自杀风险。氯胺酮是一种 N-甲基-D-天冬氨酸(NMDA)受体拮抗剂,可迅速缓解抑郁症状并降低自杀倾向,这可能是通过降低外侧缰核(LHb)脑核的过度活跃来实现的。在这里,我们发现,在人类抑郁症的大鼠模型中,阿片类拮抗剂会消除氯胺酮降低抑郁样行为和 LHb 过度活跃细胞表型的能力。然而,单独激活阿片受体本身不足以产生氯胺酮样效果,氯胺酮也不会模拟阿片类药物的快感效应,这表明阿片系统不会介导氯胺酮的作用,而是允许其发挥作用。因此,氯胺酮不是阿片类药物,但它的作用需要 NMDA 和阿片受体信号,这表明这两种神经递质系统之间的相互作用对于实现抗抑郁作用是必要的。